The recent article by Rossing et al. (1) raises familiar concerns regarding basic principles on screening. Despite a universally acknowledged deficiency (ie, no premalignant condition), investigators continue to attempt to "screen" for earlier stage ovarian cancer and not for a premalignant condition. These efforts are commendable, and more research should be encouraged.
In fairly recent reports (1,2) on the early detection of ovarian cancer by symptoms, the consensus recommendations state that in a woman with ovarian cancer symptoms that include bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, and urinary urgency or frequency almost daily for more than a few weeks should consult her physician with the hope that prompt evaluation may lead to earlier diagnosis of ovarian cancer and improved outcomes. However, even the carefully worded, balanced, and erudite consensus recommendations of expert organizations cannot avoid the potential for harm.
Harm occurs from the public interpretation of these reports that lead to anxiety for patients and providers. The recent optimism regarding a symptom index has led to numerous calls from health-care providers who fear having potentially delayed diagnosing ovarian cancer among their patients with these common complaints. Patients similarly present with self-diagnosis of ovarian cancer, leading to unnecessary test and expenses. Real harm occurs if or when patients then ignore subsequent symptoms because of the experience of their first false-positive result. After popular news stories that report on any new screening algorithm, resources are drained from the health-care system when nonspecific symptoms are pursued and then even more resources are drained by the inevitable frivolous lawsuits, which result in part from seminars and courses held by attorneys to promote liability that is based on potentially missed or delayed diagnoses. We attempted to verify the possible earlier detection of ovarian cancer by use of the known relationship between dermatomyositis or polymyositis and ovarian cancer. Among patients with dermatomyositis or polymyositis, the rates of cancer and cancer mortality are increased (3). Our hypothesis was that if symptoms could detect a premalignant or earlier stage disease, then patients with dermatomyositis or polymyositis could experience some benefit including an earlier diagnosis as a result of their symptoms. In our case-control analysis of patients with dermatomyositis or polymyositis and ovarian cancer (52 case patients and 14 control subjects), we were unable to detect any advantage (eg, earlier stage or grade) in patients being intensively screened for ovarian cancer in this highrisk population (4) .
Ovarian cancer remains difficult to detect at an early stage mostly because there is no premalignant condition and no detectable early characteristics. Certainly symptoms can help the clinician, but they may not be able to help anyone (patient, doctor, or society) in the long term.
